Clinical trials
Dermatomyositis (DM) clinical trials
Below are recruiting dermatomyositis (dm) clinical trials, each written for real people, not researchers. We’re tracking 6 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07111065RecruitingPhase 2
Fatty Acid Supplement for Dermatomyositis
This study tests whether taking a fatty acid supplement (omega-3) for 6 months can help reduce disease activity in people with dermatomyositis. Participants will also receive dietary coaching and have regular check-ups at the NIH to monitor their progress.
Bethesda, MarylandAges 18–60 - NCT07265999Recruiting
Severity factors of dermatomyositis in Caribbean patients
This study looks at what makes dermatomyositis more severe in people of Caribbean background living in Guadeloupe. By understanding these factors, doctors may better manage this rare muscle and skin disease.
Pointe-à-PitreAges 16 years+ - NCT06371417RecruitingPhase 1
Testing RAY121 for several immune diseases (RAINBOW trial)
This trial tests a new medicine called RAY121 (an antibody) for people with certain autoimmune diseases. It aims to see if RAY121 is safe and how the body handles it. If you have one of these conditions and meet the basic health requirements, you might be able to join.
Orange, CaliforniaAges 18–85 - NCT06723106Enrolling by invitationPhase 1
Long-term safety study of RAY121 for immune conditions
This study is for people who already took RAY121 in a previous trial and did well. It tests whether continuing the treatment is safe and effective over a longer period. The goal is to manage chronic immune conditions.
Camperdown, New South WalesAges 18–85 - NCT05895786RecruitingPhase 3
Study drug for active dermatomyositis or polymyositis
This Phase 3 trial tests how an investigational medicine (PF-06823859) works in adults with active dermatomyositis or polymyositis. It aims to improve disease control by targeting the immune system, but you must meet several safety and diagnosis requirements.
Glendale, ArizonaAges 18 years+ - NCT07377058Recruiting
Tocilizumab study for anti-MDA5 positive dermatomyositis
This trial tests if adding the drug tocilizumab to standard therapy helps people with a rare type of dermatomyositis (anti-MDA5 positive) that often affects the lungs. It compares tocilizumab to a placebo to see if it can improve symptoms and lung function.
Beijing, Beijing MunicipalityAges 18–65
Hear when a new Dermatomyositis (DM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for dermatomyositis (dm)?
- Yes. Clin2 currently lists 6 recruiting dermatomyositis (dm) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a dermatomyositis (dm) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a dermatomyositis (dm) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.